These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 121849)

  • 61. Therapeutic effects of adding rimactane (rifampicin) 450 milligrams daily or 1200 milligrams once monthly in a single dose to dapsone 50 milligrams daily in patients with lepromatous leprosy.
    Languillon J; Yawalkar SJ; McDougall AC
    Int J Lepr Other Mycobact Dis; 1979 Mar; 47(1):37-43. PubMed ID: 376454
    [No Abstract]   [Full Text] [Related]  

  • 62. 4:4 diacetyl-diamino-diphenyl sulphone in the treatment of leprosy.
    Kundu S; Ghosh S
    Bull Calcutta Sch Trop Med; 1972 Apr; 20(2):30-1. PubMed ID: 4666676
    [No Abstract]   [Full Text] [Related]  

  • 63. Ecological considerations on treatment of leprosy.
    Bergel M
    Nihon Rai Gakkai Zasshi; 1983; 52(1):58-61. PubMed ID: 6381451
    [No Abstract]   [Full Text] [Related]  

  • 64. 'Pulsed' rifampicin therapy in leprosy. A clinical study.
    Girdhar BK; Desikan KV
    Lepr India; 1979 Oct; 51(4):475-80. PubMed ID: 392192
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Efficacy of combined treatments comprising 6 months' administration of rifampicin in multibacillary leprosy].
    Pattyn SR; Husser JA; Saint-André P
    Acta Leprol; 1986; 4(4):445-6. PubMed ID: 3296614
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Combined treatments consisting of rifampicin in periodic doses: the experience in Niger].
    Soga G; Blanc L; Alfa C; Grosset J; Xavier S
    Acta Leprol; 1986; 4(4):397-407. PubMed ID: 3296609
    [No Abstract]   [Full Text] [Related]  

  • 67. Clinical trial of DADDS in lepromatous leprosy.
    Ganapati R; Naik SS; Shah MH; Shirsat LS; Gaitonde BB
    Lepr India; 1976 Jul; 48(3):238-43. PubMed ID: 799207
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Follow up study of thirty-six borderline cases of leprosy.
    Kundu S; Ghosh S
    Bull Calcutta Sch Trop Med; 1967 Jul; 15(3):103-4. PubMed ID: 5616299
    [No Abstract]   [Full Text] [Related]  

  • 69. Ocular leprosy in West Malaysia. Search for a posterior segment lesion.
    Weerekoon L
    Br J Ophthalmol; 1972 Feb; 56(2):106-13. PubMed ID: 5010311
    [No Abstract]   [Full Text] [Related]  

  • 70. DNA damage studies in untreated and treated leprosy patients.
    Gandhi G; Singh B
    Mutagenesis; 2004 Nov; 19(6):483-8. PubMed ID: 15548761
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [The pharmacokinetics of rifampicin in the intermittent treatment of patients with pulmonary tuberculosis. 2. The effect of rifampicin on the course of therapy for mycobacteriosis and non-tubercular infectious diseases].
    Eule H; Werner E; Winsel K; Iwainsky H
    Pharmazie; 1985 Apr; 40(4):276-7. PubMed ID: 4011667
    [No Abstract]   [Full Text] [Related]  

  • 72. Dapsone syndrome--a case report.
    Khare AK; Bansal NK; Meena HS
    Indian J Lepr; 1987; 59(1):106-9. PubMed ID: 3611856
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Lepromatous leprosy after BCG vaccination].
    Texier L; Maleville J; Geniaux M; Gauthier O; Delaunay MM
    Med Cutan Ibero Lat Am; 1975; 3(5):381-2. PubMed ID: 1084945
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Rifampin 1200 mg once monthly together with daily Lamprene and dapsone in treatment of refactory patients with lepromatous leprosy.
    Paul S; Rose ET
    Int J Lepr Other Mycobact Dis; 1981 Sep; 49(3):342-3. PubMed ID: 7198625
    [No Abstract]   [Full Text] [Related]  

  • 75. [Efficacy of a daily dosage of dapsone combined with a single dose of rifampicin. Clinical, bacteriological and histopathological evaluation].
    Le KD; Nguyen N; Nguyen VM
    Acta Leprol; 1981; 85():75-82. PubMed ID: 6805238
    [No Abstract]   [Full Text] [Related]  

  • 76. [Treatment of leprosy with diucifon].
    Goloshchapov NM; Steklovskiĭ VK; Filipskikh TP; Khromova EB
    Vestn Dermatol Venerol; 1983 Apr; (4):67-71. PubMed ID: 6868818
    [No Abstract]   [Full Text] [Related]  

  • 77. [Short-term clinical and histological evaluation of combination drug therapy of leprosy in Mayotte].
    Cnudde F; Julvez J; Rivière JP
    Acta Leprol; 1987; 5(2):115-24. PubMed ID: 3303804
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The rate of relapse in lepromatous leprosy following completion of twenty years of supervised sulphone therapy.
    Waters MF; Rees RJ; Laing AB; Khoo Kah Fah ; Meade TW; Parikshak N; North WR
    Lepr Rev; 1986 Jun; 57(2):101-9. PubMed ID: 3747702
    [No Abstract]   [Full Text] [Related]  

  • 79. [Therapeutic effect of rifampicin (RFP) on leprosy. IV. Serological examination (author's transl)].
    Abe M; Minagawa F; Yoshino Y
    Repura; 1974; 43(1):45-51. PubMed ID: 4479676
    [No Abstract]   [Full Text] [Related]  

  • 80. [In vitro immunologic changes in 4 patients with lepromatous leprosy and 4 patients with borderline leprosy treated with Neisseria perflava for 17 to 25 months].
    Saint-André P; Ferracci C; Travi Piacentile M; Baquillon G
    Acta Leprol; 1979; (76-77):291-3. PubMed ID: 121847
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.